Clinical Guidelines & Pathways


Treatment pathway for Potassium Binders for persistent hyperkalaemia patients with chronic kidney disease (stages 3b-5) or heart failure, based on NICE TA 599 & 626.


Accepted for use with permission, and ratified by Bedfordshire, Luton and Milton Keynes Area Prescribing Committee, June 2022.

View Document

Guideline Categories: Miscellaneous, Renal

Guideline Areas: Bedfordshire, Luton, Milton Keynes

Guideline Tags: binders, chronic kidney disease, hyperkaelaemia, kidney, Patiromer, potassium, sodium zirconium cyclosilicate

Please use the search box to search the whole site if you can't find what you're looking for:

To top
Welcome to the BLMK Medicines Optimisation website.
This site is currently being updated.

If you have any feedback or find any issues, please email the team:
BLMKICB.MedsOpt@nhs.net